Integrated BioTherapeutics, Inc. (IBT) is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT’s pipeline includes promising product candidates for bacterial and viral infections. IBT’s bacterial program is focused on countermeasures against staphylococcal infections, primarily by targeting a variety of toxins produced by S. aureus. IBT’s S. aureus vaccine, now spun off into Integrated BioTherapeutic Vaccines, is entering the clinic in 2022. IBT’s antiviral pipeline includes unique Ebola and Marburg antibody therapeutics, vaccines for filoviruses and Nipah virus, and a strong discovery pipeline for emerging viruses. Further, IBT developed a novel antibody engineering technology for targeting anti-toxin antibodies to the surface of bacteria, integrating toxin neutralization with effector functions.
In addition to the active anti-infectious disease discovery pipeline at IBT, we also operate a CRO business called IBT Bioservices which provides state of the art infectious disease discovery capabilities critical reagents as well as animal model testing services to industrial and academic clients.
Located in Rockville, Maryland, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and many biotechnology and pharmaceutical companies and academic laboratories.